Leerink Partnrs Comments on Nkarta FY2029 Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Research analysts at Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Nkarta in a report issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the company will post earnings of ($1.74) per share for the year. The consensus estimate for Nkarta’s current full-year earnings is ($1.68) per share.

Several other analysts also recently issued reports on NKTX. Needham & Company LLC decreased their price target on Nkarta from $13.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, November 8th. Mizuho decreased their price target on Nkarta from $20.00 to $16.00 and set an “outperform” rating for the company in a research note on Thursday, November 21st. Finally, HC Wainwright decreased their price target on Nkarta from $22.00 to $18.00 and set a “buy” rating for the company in a research note on Monday, November 11th. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $15.00.

Nkarta Stock Performance

NKTX opened at $2.21 on Friday. The company has a market cap of $155.96 million, a PE ratio of -1.18 and a beta of 0.85. The stock has a 50-day moving average of $2.36 and a 200-day moving average of $3.66. Nkarta has a 52-week low of $1.96 and a 52-week high of $16.24.

Insider Buying and Selling

In related news, CEO Paul J. Hastings sold 17,378 shares of the business’s stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the transaction, the chief executive officer now owns 319,859 shares of the company’s stock, valued at approximately $703,689.80. The trade was a 5.15 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 8.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Nkarta

Several large investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD raised its holdings in Nkarta by 41.5% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,958 shares of the company’s stock valued at $60,000 after acquiring an additional 7,030 shares in the last quarter. Hsbc Holdings PLC raised its holdings in Nkarta by 102.8% in the 4th quarter. Hsbc Holdings PLC now owns 73,845 shares of the company’s stock valued at $171,000 after acquiring an additional 37,433 shares in the last quarter. Stifel Financial Corp raised its holdings in Nkarta by 11.5% in the 4th quarter. Stifel Financial Corp now owns 90,811 shares of the company’s stock valued at $226,000 after acquiring an additional 9,359 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Nkarta by 101.1% in the 4th quarter. Dimensional Fund Advisors LP now owns 569,357 shares of the company’s stock valued at $1,417,000 after acquiring an additional 286,181 shares in the last quarter. Finally, Wasatch Advisors LP raised its holdings in Nkarta by 37.4% in the 4th quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company’s stock valued at $6,277,000 after acquiring an additional 686,229 shares in the last quarter. Institutional investors and hedge funds own 80.54% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.